GLP1R and diabetic kidney disease: In real clinical practice, with the assistance of RAS inhibitors, SGLT2 inhibitors, and GLP-1 receptor agonists, finerenone safely and effectively reduces the urinary protein levels in DKD patients and ameliorates glomerular and tubular function, delaying disease progression.